The design and development of a new class of small 2,6-disubstituted piperidine N-arylsulfonamide gamma-secretase inhibitors is reported. Lowering molecular weight including the use of conformational constraint led to compounds with less CYP 3A4 liability compared to early leads. Compounds active orally in lowering Abeta levels in Tg CRND8 mice were identified as potential treatments for Alzheimer's disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2007.08.013 | DOI Listing |
Publication Analysis
Top Keywords
gamma-secretase inhibitors
8
small conformationally
4
conformationally restricted
4
restricted piperidine
4
piperidine n-arylsulfonamides
4
n-arylsulfonamides orally
4
orally active
4
active gamma-secretase
4
inhibitors design
4
design development
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!